-
Real Time Chart
-
Stock Profile
-
Stock Fundamentals
Balance Sheet
-
Symbol Info
-
Symbol Over View
-
Technical Analysis
URGN stock profile
UroGen Pharma Ltd Company Profile
Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
Company information
- Company Name UroGen Pharma Ltd
- Industry Pharmaceutical Preparation Manufacturing
- CEO Elizabeth Barrett
- Security Name UroGen Pharma Ltd
- Sector Manufacturing
- Employees 195
- Exchange NASDAQ
- Country Israel
- State Raanana
- City 9 Hataasiya St
- Address
- Phone 97297707601
- Website https://www.urogen.com
- Zip 4365007
CEO Compensation
- Name Ron Bentsur
- Location New York, NY
- Symbol URGN
- Salary 610200
- OptionAwards 1739588
- OtherComp 3266324
- Total 5950112
- PensionAndDeferred 0
- Exchange
- StockAwards 0
- Bonus 0
- Year 2018
Peers
- OVAT-CA
- OVID
- OVIT
- OYST
Top Executives
- Entity Name
- Position
- Report Date
-
Belldegrun Arie100002022-06-10
-
BUTITTA CYNTHIA M100002022-06-10
-
Cohen Fred E100002022-06-10
-
Holden Stuart100002022-06-10
-
Nussbaum Ran31832022-06-10
-
Schoenberg Mark15002022-05-03
-
Kim Dong2022-03-29